Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

0.8351 -0.0869 (-9.43%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Silo Pharma Stock Gaining Today?
Silo Pharma stock is rising after announcing a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 chronic pain treatment. 
Via Benzinga
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Promising Preclinical Results for SPC-15 in Treating Severe Psychiatric Disorders
Via Investor Brand Network
Exposures Product Safety
Why Is Silo Pharma (SILO) Stock Up 60% Today?
With developmental-stage Silo Pharma inking a partnership to forward PTSD drugs, SILO stock shot higher on the credibility boost. 
Via InvestorPlace
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Promising Results from Testing of Ketamine-Loaded Implant for Chronic Pain Relief
Via Investor Brand Network
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports on FDA Pre-IND Meeting to Advance Development of Lead Program
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic
Via Investor Brand Network
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Agreement to Launch New Study of SPU-16 Homing Peptide for Multiple Sclerosis
Via Investor Brand Network
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference
Via Investor Brand Network
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Crude Oil Down 3%; Netflix Earnings Top Estimates
Via Benzinga
Exposures Fossil Fuels
Why Selective Insurance Group Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering
Via Investor Brand Network
Gold Down 2%; SLB Posts Upbeat Earnings
Via Benzinga
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug
Silo Pharma stock soared on high trading volume after announcing a partnership with Resyca BV for developing an intranasal PTSD treatment. The collaboration aims to enhance drug delivery to the brain,... 
Via Benzinga
Dow Dips 250 Points; US Weekly Jobless Claims Surge
Via Benzinga
Topics Stocks
Exposures US Equities
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters Device and CMC Development Master Plan to Support IND-Enabling Study of SPC-15
Via Investor Brand Network
US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings
Via Benzinga
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.